Two mutations of basic residues within the N-terminus of HMG-1 B domain with different effects on DNA supercoiling and binding to bent DNA
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
11294645
DOI
10.1021/bi002741i
PII: bi002741i
Knihovny.cz E-resources
- MeSH
- DNA Adducts metabolism MeSH
- Arginine genetics MeSH
- Circular Dichroism MeSH
- Cisplatin pharmacology MeSH
- DNA-Binding Proteins biosynthesis genetics metabolism MeSH
- Nucleic Acid Conformation * drug effects MeSH
- Rats MeSH
- Lysine genetics MeSH
- Molecular Sequence Data MeSH
- Mutagenesis, Site-Directed * MeSH
- Peptide Fragments biosynthesis genetics metabolism MeSH
- HMGB1 Protein MeSH
- High Mobility Group Proteins biosynthesis genetics metabolism MeSH
- Amino Acid Sequence MeSH
- Amino Acid Substitution genetics MeSH
- DNA, Superhelical drug effects genetics metabolism MeSH
- Protein Structure, Tertiary genetics MeSH
- Carrier Proteins biosynthesis genetics metabolism MeSH
- Protein Binding genetics MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- DNA Adducts MeSH
- Arginine MeSH
- Cisplatin MeSH
- DNA-Binding Proteins MeSH
- Lysine MeSH
- Peptide Fragments MeSH
- HMGB1 Protein MeSH
- High Mobility Group Proteins MeSH
- DNA, Superhelical MeSH
- Carrier Proteins MeSH
High mobility group (HMG) 1 protein and its two homologous DNA-binding domains, A and B ("HMG-boxes"), can bend and supercoil DNA in the presence of topoisomerase I, as well as recognize differently bent and distorted DNA structures, including four-way DNA junctions, supercoiled DNA and DNA modified with anticancer drug cisplatin. Here we show that the lysine-rich part of the linker region between A and B domains of HMG-1, the (85)TKKKFKD(91) sequence that is attached to the N-terminus of the B domain within HMG-1, is a prerequisite for a preferential binding of the B domain to supercoiled DNA. The above sequence is also essential for a high-affinity binding of the B domain to DNA containing a site-specific major 1,2-d(GpG) intrastrand DNA adduct of cisplatin. Mutation of Arg(97), but not Lys(90) [Lys(90) forms a specific cross-link with platinum(II) in major groove of cisplatin-modified DNA; Kane, S. A., and Lippard, S. J. (1996) Biochemistry 35, 2180--2188], to alanine significantly (>40-fold) reduces affinity of the B domain to cisplatin-modified DNA, inhibits the ability of the B domain to bend (ligase-mediated circularization) or supercoil DNA, and results in a loss of the preferential binding of the B domain to supercoiled DNA without affecting the structural-specificity of the HMG-box for four-way DNA junctions. Some of the reported activities of the B domain are enhanced when the B domain is covalently linked to the A domain. We propose that binding of the A/B linker region within the major DNA groove helps the two HMG-1 domains to anchor to the minor DNA groove to facilitate their DNA binding and other activities.
References provided by Crossref.org
Histone H1 Differentially Inhibits DNA Bending by Reduced and Oxidized HMGB1 Protein
HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha
Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog
HMGB1 interacts with human topoisomerase IIalpha and stimulates its catalytic activity